ESMO 2022 | EpCAM-targeted CAR T-cell therapy for advanced colorectal and gastric tumors

Weijia Fang, Zhejiang University, Hangzhou, China, discusses the rationale behind targeting epithelial cell adhesion molecule (EpCAM) in chimeric antigen receptor (CAR)-T cell therapies for patients with advanced colorectal and gastric cancers. Whilst EpCAM is expressed in low amounts in normal gastrointestinal and biliary tissue, they are usually located on the basal side of epithelial tissue. EpCAM is also involved in activation of the Wnt signaling pathway, which is involved in tumorigenesis. Dr Fang additionally highlights the Phase I trial (NCT05028933) assessing EpCAM-targeted CAR-T cell therapies in advanced gastrointestinal cancers. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.